http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI1003742-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_108b25fa685b8bfe839560275d7d9436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5413f7499f2df1e000d4fd5fda8a6965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90eb13f24b49ad640b6c6cf045ab8626 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9bb8303823580c0b8ed267ac32ead96f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-686 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate | 2010-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c11cfc23341917ac329275fd1ae9bf91 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a74f015836a9871dae5eae1e99e9a7a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92fadcf2e0f30ed48eeab7ed324807d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fcee1fc3f2bf8e8978388dca65a1e96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74427c738bd4581a2be0c845e9beded4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_374bfd5db0a34b35c57817fad3f85d8d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00a8f555fffb1f0965cda48fb38ec5f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58b97ecaf6c85c42fc18eff6bf9a4465 |
| publicationDate | 2021-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI1003742-B1 |
| titleOfInvention | COMBINED USE OF MOLECULAR TECHNIQUES AND BIOMARKERS FOR PROSTATE CANCER MONITORING AND DIAGNOSIS |
| abstract | COMBINED USE OF MOLECULAR TECHNIQUES AND BIOMARKERS FOR PROSTATE CANCER MONITORING AND DIAGNOSIS The present invention provides methods for monitoring and therapeutic efficacy for patients with prostate cancer, by the combined use of molecular biology techniques, specifically the RT-PCR Semi-technology. Quantitative; Relative Quantitative; Absolute Quantitative and Duplicate (Nested) components and reaction conditions to estimate or detect levels of RNA specimens of the SRD5A2, PCA3, LSP1 and RNASEL genes differentially expressed in prostate tissues of patients with adenocarcinomas, comparing them to benign prostatic diseases (hyperplasias , prostatic infections, among others) and/or healthy young individuals. This invention also relates to the combined use of the expression of these molecular biomarkers in peripheral blood, to monitor the presence or absence of circulating prostate cells and/or micrometastatic cells in the peripheral blood of patients with prostate cancer. This invention has direct application in distinguishing between patients with prostate cancer and benign hyperplasia, as well as in choosing the most appropriate therapy, according to the stage of the disease, and in monitoring the therapeutic efficacy and relapse of the disease after treatment. |
| priorityDate | 2010-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 223.